drugset / Trial / NCT03926819
A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
Phase 1
Completed
20 enrolled
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with single ascending doses (SAD), followed by multiple dose with doses daily for 7 days.
Timeline
- Start
- 2022-07-25
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HBI-002 | Unknown | — | Oral |